Table 3 Dose of non-steroidal anti-inflammatory drugs (NSAID) use and risk of pancreatic cancer
From: Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study
Period of NSAID use | |||||||||
|---|---|---|---|---|---|---|---|---|---|
5 years before index date, excluding the year before index date | Until 1 year before index date | ||||||||
NSAID dose (DDDs) | Cases ( n) | Controls ( n) | OR (95% CI) | Adjusted OR (95% CI) a | NSAID dose (DDDs) | Cases ( n) | Controls ( n) | OR (95% CI) | Adjusted OR (95% CI) a |
No use: 0 | 534 | 3776 | 1.0 | 1.0 | No use: 0 | 345 | 2565 | 1.0 | 1.0 |
Category 1: 0–9.20 | 156 | 1058 | 1.04 (0.86–1.26) | 0.98 (0.80–1.20) | Category 1: 0–31.5 | 192 | 1354 | 1.06 (0.88–1.28) | 1.01 (0.83–1.23) |
Category 2: 9.25–26.50: | 145 | 1059 | 0.97 (0.80- 1.18) | 0.91 (0.74–1.11) | Category 2: 31.55–90.5 | 217 | 1357 | 1.20 (1.00–1.43) | 1.11 (0.91–1.34) |
Category 3: 26.55–100.50: | 160 | 1020 | 1.11 (0.92- 1.35) | 1.04 (0.85–1.27) | Category 3: 90.55–298 | 198 | 1333 | 1.11 (0.92–1.35) | 1.03 (0.84–1.26) |
Category 4: >100.50 | 146 | 1041 | 0.99 (0.81–1.21) | 0.93 (0.77–1.15) | Category 4: >298 | 189 | 1345 | 1.05 (0.87–1.28) | 0.96 (0.78–1.18) |
